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Abstract
Aims/hypothesis We evaluated the secular trend of glycaemic control in individuals with type 2 diabetes in developing countries,
where data are limited.
Methods The International Diabetes Management Practices Study provides real-world evidence of patient profiles and diabetes
care practices in developing countries in seven cross-sectional waves (2005–2017). At each wave, each physician collected data
from ten consecutive participants with type 2 diabetes during a 2 week period. The primary objective of this analysis was to
evaluate trends of glycaemic control over time.
Results A total of 66,088 individuals with type 2 diabetes were recruited by 6099 physicians from 49 countries. The proportion of
participants with HbA1c <53 mmol/mol (<7%) decreased from 36% in wave 1 (2005) to 30.1% in wave 7 (2017) (p < 0.0001).
Compared with wave 1, the adjusted ORs of attaining HbA1c ≤64 mmol/mol (≤8%) decreased significantly in waves 2, 5, 6 and 7
(p < 0.05). Over 80% of participants received oral glucose-lowering drugs, with declining use of sulfonylureas. Insulin use increased
from 32.8% (wave 1) to 41.2% (wave 7) (p < 0.0001). The corresponding time to insulin initiation (mean ± SD) changed from 8.4 ±
6.9 in wave 1 to 8.3 ± 6.6 years in wave 7, while daily insulin dosage ranged from 0.39 ± 0.21 U/kg (wave 1) to 0.33 ± 0.19 U/kg
(wave 7) for basal regimen and 0.70 ± 0.34 U/kg (wave 1) to 0.77 ± 0.33 (wave 7) U/kg for basal–bolus regimen. An increasing
proportion of participants had ≥2 HbA1c measurements within 12 months of enrolment (from 61.8% to 92.9%), and the proportion
of participants receiving diabetes education (mainly delivered by physicians) also increased from 59.0% to 78.3%.
Conclusions In developing countries, glycaemic control in individuals with type 2 diabetes remained suboptimal over a 12 year
period, indicating a need for system changes and better organisation of care to improve self-management and attainment of
treatment goals.
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Introduction
Diabetes affects approximately 463 million people world-
wide, of whom 90% have type 2 diabetes, and the prevalence
is expected to increase by 51% by 2045. A large number of
people with diabetes live in developing regions, with esti-
mates suggesting that 55 million people in the Middle
East/North Africa, 32 million in South and Central America,
19 million in sub-Saharan Africa and 88 million in South East
Asia have diabetes [1].
Poor glycaemic control can lead to an increased risk of
blindness, end-stage renal disease, cardiovascular disease
and lower limb amputations [2]. In 2012, 1.5 million deaths
worldwide were directly caused by diabetes [2]. A further 2.2
million deaths were due to cardiovascular disease, chronic
kidney disease and tuberculosis, associated with high blood
glucose levels [2]. Optimal blood glucose control is therefore
needed to reduce the risk of complications and premature
death in developing regions, which have a high burden of
diabetes and possess fewer resources to treat end-stage
disease, creating a considerable impact on healthcare systems.
Over the last decade, there have been major advances in
diabetes management, resulting in improved outcomes for
individuals with type 2 diabetes. These include the introduc-
tion of novel technologies, newer oral glucose-lowering drugs
(OGLD; e.g. sodium–glucose cotransporter [SGLT]2 inhibi-
tors, dipeptidyl peptidase 4 inhibitors [DPP-4i] and glucagon-
like peptide-1 receptor agonists [GLP-1 RA]), insulin thera-
pies and delivery systems/devices.
While the majority of guidelines consider an HbA1c goal of
53 mmol/mol (<7%) to be appropriate in most individuals
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with diabetes, use of individualised HbA1c goals are recom-
mended, based on patient preferences, characteristics, comor-
bidities and risk of adverse events [3–9]. These individualised
goals can range from <48 mmol/mol (<6.5%) in individuals
with low hypoglycaemia risk and <64 mmol/mol (<8%) in
high-risk patients, such as those with a history of severe
hypoglycaemia, extensive comorbidities or complications,
older individuals or those with long-standing diabetes [3–9].
Self-management is a cornerstone in diabetes care and
provision of diabetes education can improve self-
management behaviours and glycaemic control [10–13].
Most professional bodies recommend the use of structured
diabetes education and support programmes delivered by
trained healthcare providers (HCPs), such as nurses, to
improve self-management, and that these education
programmes should be given at the time of diagnosis [3–9].
According to the International Diabetes Federation guidelines,
for every primary care facility, at least one HCP should be
trained as a diabetes educator, and these facilities should
provide regular, structured group education to support individ-
uals when needed [5].
In anticipation of increasing disease awareness, better
care standards and technological advancements, the
International Diabetes Management Practices Study
(IDMPS) was designed to document and track patient
profiles and patterns of care across time in developing
countries, where data are limited. The IDMPS is the largest
international observational study with the participation of
over 6000 physicians from 49 countries across Africa, the
Middle East, South Asia, Latin America, Asia and Eurasia.
Data were collected using structured case report forms in a
series of yearly ‘waves’, with each wave recruiting a differ-
ent cohort of participants. The first wave of data collection
began in 2005 and the most recent wave (wave 7) was
completed in 2017. Apart from a standard dataset collected
in all waves, each wave had a particular theme, such as
understanding factors involved in glycaemic control (wave
1), healthcare resource utilisation (wave 2), barriers to
insulin therapy (wave 3), hypoglycaemia (wave 4), symp-
toms of depression (wave 5), self-management (wave 6)
and insulin discontinuation (wave 7) [10, 14–17].
Results from previous waves have demonstrated the low
attainment of treatment goals for LDL-cholesterol
(<2.6 mmol/ l ) , BP (<130/80 mmHg) and HbA1c
(53 mmol/mol [<7%]) with only 25% of participants with type
1 diabetes and 36% of participants with type 2 diabetes
achieving HbA1c of 53 mmol/mol (<7%); <8% of participants
achieved all three goals [14]. Data analysis from other waves
has demonstrated the positive associations of good glycaemic
control with patient education and self-monitoring of blood
glucose (SMBG) [10], in addition to the positive association
of diabetes-related complication rates and increased
healthcare resource utilisation [15, 17].
The present analysis of real-world data describes glycaemic
goal achievement, therapy use and care management practices
in people with type 2 diabetes over time, from the first wave of
IDMPS data collection (2005) to the most recent wave (2017).
Methods
Study design and participants
The IDMPS is an ongoing international, multicentre,
non-interventional, observational study, which docu-
ments current practices in diabetes management. From
2005 to 2017, data were collected in seven individual
waves, each wave enrolling different patients and physi-
cians. At each wave, during a 2 week period, partici-
pating physicians were asked to enter details of the first
five patients with type 1 diabetes (data not shown) and
ten patients with type 2 diabetes who made a routine
visit, using structured care report forms. Participating
physicians included both general practitioners and
specialists, providing they had experience of caring for
individuals with diabetes and prescribing insulin thera-
py. Physicians were randomly selected following strati-
fication for specialty. Study design and reporting format
are in accordance with the recommended STROBE
(Strengthening the Reporting of Observational Studies
in Epidemiology) guidelines. Ethics approval was
obtained from institutional review boards in each coun-
try. The study was conducted in accordance with the
Declaration of Helsinki. Data from all seven waves are
presented herein.
Inclusion/exclusion criteria
Men and women above the lower legal age limit (country-
specific) with a clinical diagnosis of type 2 diabetes who
provided informed consent were eligible for inclusion.
Exclusion criteria included concomitant participation in
another clinical study, participation in a previous IDMPS
wave and current receipt of temporary insulin therapy due to
gestational diabetes, surgery or pancreatic cancer.
Outcome measures
In this analysis, we examined the secular trend of glycaemic
control and use of medications (i.e. insulin and/or OGLD) in
individuals with type 2 diabetes over a 12 year period in 49
countries across Africa, the Middle East, South Asia, Latin
America, Asia and Eurasia.
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Statistical analysis
Data collection Patient information was recorded by the
attending physician using individual case report forms during
the 2 week study period.
Baseline variables and demographic characteristics
Evaluation variables were recorded by participating physi-
cians and included the proportion of participants attaining
recommended and individualised glycaemic goals according
to their characteristics and treatments. Due to the non-
interventional nature of the survey, no safety data were collect-
ed. Spontaneous adverse drug reactions were reported accord-
ing to country-specific regulations.
Analysis populations All individuals who fulfilled eligibility
criteria and had no missing data concerning the treatment for
diabetes defined as OGLD [yes/no] and insulin [yes/no] were
included in the eligible population for analysis. Sample size
was estimated assuming that insulin is the least prescribed ther-
apy (in terms of proportion) to give an absolute precision of
20% and a CI of 95%. Data were analysed in the overall type 2
diabetes population and stratified by treatment subgroups
including OGLD only, OGLD + insulin and insulin only.
Data analyses Results presented are based on real-world data
from all seven waves. Quantitative variables are expressed as
mean ± SD and qualitative variables are expressed as numbers
and percentages. No imputation was made for missing data,
with the exception of age (missing date of birth was set to ‘15’
and missing month of birth was set to ‘June’); missing data
were not counted in the percentages. Trend analyses were
conducted on all-wave data to assess the significance of
changes over time for key variables including last HbA1c
measurement, HbA1c goal attainment, current insulin use,
BMI and waist circumference recorded at enrolment.
Statistical approaches for trends analyses varied depending
on the data sets: categorical variables (e.g. HbA1c
<53/≥53 mmol/mol [<7/≥7%] or yes/no) were assessed using
a two-sided Cochran–Armitage test to investigate the relation-
ship between study waves and the variables of interest, assum-
ing a no-trend null hypothesis; continuous variables were
assessed using a least-squares fit value (R2). We used logistic
regression models to explore the trend of attainment of HbA1c
<53 mmol/mol (<7%) over time across all waves; data were
adjusted for age, sex, treatment regimen, disease duration and
diabetes education. While an HbA1c goal of <53 mmol/mol
(<7%) is considered appropriate for many people with type 2
diabetes, guidelines state the importance of individualised
goals, the highest of which is <64 mmol/mol (<8%) [3–9].
Consequently, achievement of HbA1c <64 mmol/mol (<8%)
was also assessed. Owing to the heterogeneity of study popu-
lations across regions and differences in regional participation
across waves, this further analysis included region as an
adjustment, in addition to the adjustments used for analysis
of HbA1c <53mmol/mol (<7%), and analyses were performed
comparing waves 2–7 individually using wave 1 as a refer-
ence. Statistical analyses were performed using SAS (software
version 9.4 [2016], SAS Institute, Cary, NC, USA).
Results
Study population and baseline characteristics
Patient populationWe included 66,088 individuals with type
2 diabetes from seven waves of data collection; of these,
42,171 (63.8%) received OGLD only, 14,529 (22.0%)
received OGLD + insulin and 7566 (11.4%) received insulin
only. Patients treated with meal plan/physical activity alone
(n = 1685, 2.5%) and those who did not use OGLD, insulin or
diet for their diabetes (n = 137, 0.2%) were excluded from this
analysis. A full list of participating countries is listed in elec-
tronic supplementary material (ESM) Table 1. A total of 49
countries were included in the seven waves of data collection,
grouped into regions with the composition of each region
varying by wave depending on logistic availability.
Baseline demographics and characteristicsDuring the 12 year
period, the mean age of participants with type 2 diabetes was
~58 years and ~52%were women. Disease duration increased
from 8.3 years in wave 1 to 9.8 years in wave 7, accompanied
by a rising trend of BMI in the whole group and in the treat-
ment subgroups (data for therapy subgroups not shown). The
proportion of participants with hypertension and
dyslipidaemia increased significantly over time by 5.3% and
19.6%, respectively (p < 0.0001 for both) (Table 1).
Achievement of glycaemic goal Mean HbA1c varied by ther-
apy type, with lower values in individuals on OGLD only
compared with those treated with OGLD + insulin or insulin
only (ESM Table 2). Last mean HbA1c measurement
increased slightly from 7.8% in wave 1 to 8.1% in wave 7
for the overall population, although this increase was not clin-
ically meaningful. Similar slight increases were shown across
the different therapy groups.
Overall, <50% of participants attained HbA1c goal
(<53 mmol/mol [<7%]) in any wave, irrespective of therapy
subgroup (Fig. 1); no difference in glycaemic control was seen
between patients treated by general practitioners and patients
treated by specialists (data not shown). Among participants
treated with insulin, <30% achieved HbA1c <53 mmol/mol
(<7%), regardless of whether they received insulin alone or
in combination with OGLD (Fig. 1a). Trends analyses showed
a significant decline in HbA1c <53 mmol/mol (<7%) goal
Diabetologia (2020) 63:711–721714
Table 1 Clinical profiles, care processes and self-monitoring in participants with type 2 diabetes at enrolment between 2005 and 2017

















Age, years (SD) 58.1 (11.5) 58.2 (11.8) 57.7 (11.8) 58.4 (11.9) 57.6 (11.2) 57.3 (10.7) 57.2 (11.1)
Female sex, n (%) 5130 (51.9) 8736 (52.2) 6458 (54.1) 2882 (54.3) 5117 (53.3) 3048 (55.6) 3291 (52.2)
Weight, kg (SD) 71.6 (14.9) 75.4 (16.0) 76.7 (16.2) 78.9 (16.5) 80.6 (16.2) 82.6 (16.7) 82.0 (16.7)
Disease duration, years 8.3 (7.1) 8.6 (7.8) 8.8 (7.7) 9.1 (8.1) 8.7 (7.3) 9.3 (7.1) 9.8 (7.4)
BMI, kg/m2 (SD) 27.1 (4.8) 28.5 (5.3) 29.0 (5.5) 29.8 (5.5) 29.6 (5.5) 30.2 (5.7) 29.8 (5.5)
Hypertension, n (%) 6029 (60.9) 10,681 (62.5) 7422 (61.0) 3254 (61.1) 6315 (66.0) 3623 (66.4) 4166 (66.2)
Dyslipidaemia, n (%) 4844 (49.3) 9609 (60.2) 7267 (62.5) 3485 (67.2) 5855 (63.4) 3449 (64.8) 3970 (68.9)
Last HbA1c measurement,
mmol/mol (SD)
61.5 (85.0) 63.2 (86.7) 62.3 (85.8) 62.6 (86.1) 64.4 (87.9) 64.1 (87.7) 64.6 (88.1)
Last HbA1c measurement, % (SD) 7.8 (1.8) 7.9 (1.9) 7.9 (2.0) 7.9 (1.9) 8.0 (1.9) 8.0 (1.8) 8.1 (1.9)
HbA1c testing, n (%) 6116 (61.8) 12,492 (76.5) 9217 (80.4) 4401 (85.5) 8399 (90.0) 4952 (92.1) 5719 (92.9)
Frequency of testing of HbA1c
during past year
1.6 (1.2) 2.2 (1.4) 2.3 (1.4) 2.2 (1.5) 2.2 (1.8) 2.2 (2.0) 2.2 (1.7)
Mean values are presented unless otherwise stated
Percentages were calculated for patients with available data; these varied by each category/wave










































































































































Fig. 1 The proportion of
participants attaining HbA1c goal
defined as: (a) <53 mmol/mol or
<7%; and (b) <64 mmol/mol or
<8%, between 2005 and 2017.
The p values show test of
significance for trend in HbA1c
goal achievement in the overall
population: (a) over all waves; or
(b) waves 2–7 vs reference wave
1. **p < 0.01, ***p < 0.001. A
two-sided Cochran–Armitage test
was used to investigate the
relationship between study waves
and the variables of interest,
assuming a no-trend null
hypothesis: (a) p < 0.0001 for
trend over all waves; (b) p =
0.0036 for wave 2 vs wave 1, p =
0.2991 for wave 3 vs wave 1, p =
0.0514 for wave 4 vs wave 1, p =
0.0011 for wave 5 vs wave 1, p =
0.0006 for wave 6 vs wave 1 and
p = 0.0017 for wave 7 vs wave 1.
HbA1c goal achievement data
were missing for 3893
participants in wave 1, 5084
participants in wave 2, 3150
participants in wave 3, 961
participants in wave 4, 1256
participants in wave 5, 548
participants in wave 6 and 608
participants in wave 7
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achievement in the overall population (p < 0.0001) and treat-
ment subgroups (p < 0.0001 for all).
Using HbA1c ≤64 mmol/mol (≤8%) as an alternative goal,
the adjusted OR of attaining HbA1c goal (using wave 1 as
reference) was significantly lower in waves 2, 5, 6 and 7
(p < 0.05 for all; Fig. 1b). Female participants, those with
disease duration >10 years and individuals living in East
Europe/Eurasia were less likely to attain HbA1c ≤ 64 mmol/
mol (≤8%) (Table 2). Age was also a factor in achievement of
this higher glycaemic goal, with individuals aged >40 years
being significantly more likely to achieve it compared with
participants aged ≤40 years; the likelihood of achieving
HbA1c ≤64 mmol/mol (≤8%) increased for each decade over
the age of 40 years (Table 2). Proportions of participants
achieving various HbA1c goals in each wave are shown in
ESM Table 3.
OGLD therapyOverall, >80% of participants were treated with
OGLD with or without insulin (Table 3). The use of sulfonyl-
urea monotherapy decreased over time, while use of metfor-
min monotherapy increased. Overall, use of other types of
OGLD was low (14.5–20.0% of participants; Table 3).
Metformin was the most commonly used monotherapy, while
sulfonylureas and DPP-4is were often second- or third-line
OGLD (ESM Table 4).
Insulin therapy The proportion of participants treated with
insulin increased from 32.8% in wave 1 to 41.2% in wave 7
(p < 0.0001; Table 4). Most participants received either basal
insulin alone or premix insulin alone in wave 1 with a similar
pattern observed in wave 7. The use of premix insulin
declined from wave 1 to 4 and increased again from waves 4
to 7, while the use of basal + prandial insulin has increased
almost threefold over time (Fig. 2/ESM Fig. 1). Analysis of
insulin type (human vs analogue; waves 6 and 7 only; ESM
Table 5) revealed that use of long-acting basal insulin
analogues increased between waves 6 and 7, but human
intermediate-acting insulin was still used by 24.4% of partic-
ipants receiving basal insulin in wave 7. Approximately 50%
Table 2 Logistic regression analysis of glycaemic goal achievement
defined as HbA1c ≤64 mmol/mol (≤8%)
Comparison p value OR (95% CI)
Wavea
Wave 2 vs wave 1 0.0036 0.90 (0.84, 0.97)
Wave 3 vs wave 1 0.2991 0.96 (0.90, 1.04)
Wave 4 vs wave 1 0.0514 0.92 (0.84, 1.00)
Wave 5 vs wave 1 0.0011 0.89 (0.83, 0.95)
Wave 6 vs wave 1 0.0006 0.87 (0.80, 0.94)
Wave 7 vs wave 1 0.0017 0.89 (0.82, 0.96)
Age (years)
40–50 vs ≤40 0.0161 1.11 (1.02, 1.21)
50–60 vs ≤40 <0.0001 1.22 (1.13, 1.33)
60–70 vs ≤40 <0.0001 1.59 (1.46, 1.72)
>70 vs ≤40 <0.0001 2.08 (1.89, 2.28)
Men vs women <0.0001 1.10 (1.06, 1.14)
Time since diagnosis ≤10 vs >10 years <0.0001 1.80 (1.73, 1.88)
Region
Africa/Asia vs Eurasia/East Europe <0.0001 1.26 (1.19, 1.33)
Middle East/Latin America vs
Eurasia/East Europe
<0.0001 1.39 (1.32, 1.47)
a HbA1c goal achievement data were missing for 3893 participants in
wave 1, 5084 participants in wave 2, 3150 participants in wave 3, 961
participants in wave 4, 1256 participants in wave 5, 548 participants in
wave 6 and 608 participants in wave 7






















Proportion of participants treated with OGLD, % 81.0 84.9 87.1 91.8 85.6 87.0 88.4
Number of OGLD treatments received
1 OGLD therapy, n (%) 3527 (35.7) 6353 (36.9) 4293 (36.0) 2304 (43.6) 4542 (47.3) 1876 (34.2) 2125 (34.6)
>1 OGLD therapy, n (%) 4478 (45.3) 8248 (47.9) 6062 (50.8) 2536 (48.0) 3672 (38.2) 2890 (52.8) 3295 (53.6)
Type of OGLD treatment receiveda
Metformin alone, n (%) – 3258 (18.9) 2517 (21.1) 1246 (23.6) 2342 (24.4) 1459 (26.6) 1638 (26.7)
Sulfonylureas alone, n (%) – 2371 (13.8) 1331 (11.2) 307 (5.8) 714 (7.4) 306 (5.6) 257 (4.2)
Metformin + sulfonylureas, n (%) – 6478 (37.6) 4726 (39.6) 2195 (41.6) 3749 (39.0) 2199 (40.1) 2281 (37.2)
Other, n (%)b – 2494 (14.5) 1781 (14.9) 1092 (20.7) 1409 (14.7) 802 (14.6) 1223 (20.0)
Percentages were calculated for patients with available data; these varied by each category/wave
a Data not available for wave 1
bDetailed information on ‘Other’ therapies is available in ESM Table 4
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of participants using prandial insulin used short-acting
analogues in waves 6 and 7 and 61.0% of those using premix
insulin received human insulin, although this proportion
decreased to 57.8% by wave 7.






















Proportion of participants treated with insulin,
%
32.8 29.8 31.5 31.8 36.7 37.9 41.2
Time to initiation of insulin treatment, years 8.4 (6.9) 9.3 (7.5) 9.6 (7.6) 10.0 (7.8) 8.4 (6.8) 8.4 (6.4) 8.3 (6.6)
Time on insulin treatment, years 5.8 (5.1) 5.0 (4.7) 3.5 (4.4) 3.5 (4.3) 3.8 (4.4) 4.5 (4.7) 4.7 (4.8)
Daily insulin dose, U
Basal alone 26.6 (14.9) 28.6 (16.9) 28.2 (16.1) 26.3 (13.7) 25.5 (13.4) 26.7 (13.8) 26.4 (15.6)
Prandial alone 35.6 (19.4) 36.1 (23.8) 30.0 (17.4) 33.6 (21.8) 28.8 (17.7) 24.2 (16.0) 38.9 (35.8)
Premix alone 36.6 (17.0) 42.1 (20.2) 44.1 (20.8) 48.8 (21.8) 42.4 (19.9) 44.6 (22.4) 44.9 (24.7)
Basal + prandial 49.9 (23.1) 56.6 (27.4) 56.2 (27.8) 57.2 (27.3) 56.9 (28.6) 62.2 (25.8) 64.0 (28.9)
Daily insulin dose (weight-adjusted), U/kg
Basal alone 0.39 (0.21) 0.39 (0.23) 0.38 (0.21) 0.36 (0.19) 0.32 (0.16) 0.33 (0.16) 0.33 (0.19)
Prandial alone 0.54 (0.29) 0.50 (0.31) 0.40 (0.22) 0.40 (0.22) 0.40 (0.27) 0.31 (0.25) 0.47 (0.32)
Premix alone 0.53 (0.24) 0.56 (0.25) 0.59 (0.27) 0.62 (0.26) 0.54 (0.25) 0.55 (0.24) 0.56 (0.28)
Basal + prandial 0.70 (0.34) 0.73 (0.34) 0.73 (0.33) 0.72 (0.34) 0.69 (0.32) 0.74 (0.30) 0.77 (0.33)











































Fig. 2 Changes in use of
insulin regimens in type 2


























Wave 4 Wave 5 Wave 6 Wave 7
A person with diabetes
A nurse
A certified diabetes educator
A dietitian/nutritionist
A physicianFig. 3 Distribution of sources
of education in participants who
received diabetes-related
education. Data on the provider of
diabetes education were not
captured in waves 1–3
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The mean time to insulin initiation in the overall type 2
diabetes population was >8 years across all waves and
remained stable over time (Table 4). Similar results were seen
when assessing the insulin only and insulin + OGLD therapy
subgroups (data not shown). The time on insulin treatment
prior to study inclusion declined over time in all individuals
treated with insulin (Table 4), especially in the OGLD + insu-
lin subgroup (data not shown). The mean daily dose of insulin
increased in all insulin regimens except for basal. The mean
daily dose for the overall insulin-treated population, adjusted
for body weight (U/kg), increased for premix insulin alone
and basal + prandial but decreased for basal alone and prandial
alone (Table 4).
Blood glucose monitoring and diabetes education The
proportion of individuals who had HbA1c testing increased
from wave 1 (61.8%) to wave 7 (92.9%), with screening typi-
cally occurring twice a year (Table 1/ESM Table 2).
Participants treated with insulin were increasingly likely over
time to own a glucose meter, but this was not reflected in the
performance of SMBG; cost was increasingly cited as a limit-
ing factor for regular SMBG testing (ESM Table 6). The over-
all proportion of participants receiving diabetes education
increased over time, irrespective of therapy subgroup (ESM
Table 7). However, based on data from waves 4–7, education
was mainly provided on an individual basis by physicians
with very few individuals attending structured diabetes educa-
tion courses (Fig. 3).
Discussion
Glycaemic control in developing countries has been persis-
tently poor over the past 12 years and is growing steadily
worse, based on real-world data captured in this large interna-
tional observational study involving over 66,000 individuals
with type 2 diabetes. This situation has developed despite
multiple advances in the field of diabetes management,
including the development of new medications proven to
improve diabetes control and clinical outcomes [18].
Most participants in this study were aged 40–65 with
8–9 years of diabetes duration, with over 80% of participants
receiving OGLD. While the use of sulfonylurea monotherapy
declined over time, use of metformin monotherapy increased
over time and metformin was the most commonly usedmono-
therapy, in line with guideline recommendations [3–9]. Few
participants received newer agents, such as SGLT2 inhibitors,
although it should be noted that these therapies were approved
relatively recently in many developing countries; as such, data
on their use are only available for wave 7. The proportion of
individuals receiving insulin also increased over time, with
use of basal + prandial insulin showing a marked increase;
despite this rise, however, there was no improvement in
glycaemic control. Newer insulin analogue therapies can
provide clinical benefits in terms of reduced glycaemic vari-
ability or hypoglycaemia risk [19], which may facilitate indi-
viduals to achieve glycaemic control; however, in developing
countries, these analogues may not be readily available due to
issues of access or cost. Data from wave 7 highlighted that a
substantial proportion of participants still received human
intermediate-acting insulins (24.4%), although long-acting
analogue use increased between waves 6 and 7. Participants
receiving prandial insulin were mainly using human regular
insulins or premix insulins.
Overall, <50% of participants achieved a glycaemic goal of
HbA1c <53 mmol/mol (<7%), and <70% achieved HbA1c
<64 mmol/mol (8%). Furthermore, only 15–25% or 45–50%
of participants treated with insulin achieved either the HbA1c
<53 mmol/mol (<7%) goal or the HbA1c <64 mmol/mol (8%)
goals, respectively. These results might be ascribed to a
combination of delayed and inappropriate insulin regimen
prescription. Logistic regression analysis was used to confirm
the declining trend of HbA1c <64 mmol/mol (<8%) goal
attainment over time. The odds of goal attainment compared
with wave 1 were significantly lower for waves 2, 5, 6 and 7
(p < 0.05 for all). Other patient groups (including younger
individuals [≤40 years], women, those with longer disease
duration [>10 years] and those from Europe/Eurasia) were
also less likely to achieve the HbA1c goal compared with their
counterparts. Visits to general practitioners or specialists did
not seem to influence achievement of glycaemic goal; any
potential difference may have been attenuated by study selec-
tion criteria requiring all physicians to have prior experience
in prescribing insulin. Additionally, individuals with poor
glycaemic control or advanced disease progression might tend
to seek specialist care.
Although there was an increase in the proportion of indi-
viduals receiving diabetes education from physicians, very
few received structured diabetes education courses delivered
by nurses, dietitians or certified diabetes instructors. This may
potentially result in a lack of sufficient contact time to help
individuals deal with day-to-day concerns.
These original findings from developing countries concur
with other reports based on IDMPS data [14, 20], and are in
line with data from developed countries indicating poor rates
of glycaemic goal attainment (<53 mmol/mol [<7%]; ~20–
40%) [21, 22], indicating that the challenge of attaining good
glycaemic control is universal. It is concerning that glycaemic
control remains poor, given the increased use of insulin over
time; it should be noted that the insulin dose of 0.3–0.7 U/kg
was comparable if not higher than that used in clinical trial
settings [23–25]. In this survey, the mean time to insulin initi-
ation was 8 years, similar to that reported in developed coun-
tries [26, 27].
Considering that >50% of participants in this study receiv-
ing OGLD and/or insulin treatment displayed an HbA1c value
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>53 mmol/mol (>7%), this is a clear indicator that the
initiation and intensification of insulin remain a major
barrier in real-world practice. The discrepancy between
doses prescribed and glycaemic control suggests possible
patient non-adherence, although this was not formally test-
ed. In this regard, quality improvement programmes imple-
mented at a system level have been shown to improve
control of cardiometabolic risk factors and clinical
outcomes in community settings; such programmes
include multidisciplinary care (with training programmes
for physicians and nurses), risk-stratified care planning and
regular structured/scheduled assessment of metabolic
control and vascular complications [28–31]. The provision
of professional diabetes education for HCPs starting in
medical colleges, together with postgraduate training, is
critically important to build capacity to help HCPs in
educating patients and improving care. An alternative
(ideally complementary) approach would be to make
changes to the practice environment to provide more inte-
grated multidisciplinary care, to ultimately provide
sustained improvements in care outcomes. Such an
approach would be conducive to promoting trustworthy
relationships and communication between patients and
HCPs, and should encompass empathetic listening, tuition
of self-management skills and ongoing support [32].
According to professional guidelines, individuals with
diabetes should receive structured diabetes education and
support programmes [3, 5]; such programmes have been
shown to improve glycaemic control, as reported in previous
waves of the IDMPS [10]. In this study, over 70% of physi-
cians reported having offered education to their patients;
however, physicians are often time-poor in comparison with
other HCPs (e.g. nurses, dietitians or certified diabetes instruc-
tors), and time is a major factor for a successful diabetes
education programme. A meta-analysis of the efficacy of
self-management education on glycaemic control in individ-
uals with type 2 diabetes reported that approximately 24 h of
contact time (e.g. face to face visits, phone calls) with HCPs
are needed to sustain a 1% reduction in HbA1c over a 12
month period [33]. There are also grounds to argue that regu-
lar follow-ups are needed, as results from a recent meta-review
indicate that post-intervention improvements in HbA1c persist
until 6 months but tend to attenuate after 12 or 24months [34].
Consultation times may also be inadequate, perhaps partly due
to the pressures of the increasing global population of people
with diabetes which may increase the number of patients each
physician treats. A recent meta-analysis of primary care physi-
cian consultation time (spanning developed and developing
countries) reported that consultation time was less than
5 min in 18 of the included countries, accounting for approx-
imately 50% of the global population, with consultation length
proportional to per capita health spending [35]. Such data as
these indicate a strong need for additional support to engage
patients and emphasise the importance of time spent talking to
individuals about their needs and concerns. However, in our
survey, <20% of participants received a structured educational
diabetes programme from any source, which could be a
contributing factor to the poor glycaemic goal achievement
observed herein. We suggest that promising methods to
improve glycaemic control would include training of nurses
and dietitians in the provision of diabetes education, a general
increase in the number of certified diabetes instructors and the
delivery of such education through structured programmes.
The affordability and ownership of blood glucose moni-
toring accessories (e.g. blood glucose monitors and test
strips) are important factors for improving self-manage-
ment. In this study, an increasing proportion of participants
possessed SMBG monitors over time, but there was also a
rise in the number of individuals citing cost as a limiting
factor for regular SMBG; in those treated with insulin,
where a greater frequency of SMBG is needed, the high
cost of strips may be a deterrent. Considered together, clin-
ical inertia, insufficient access to structured diabetes
education, infrequent SMBG and high cost of monitoring
accessories/medications may all contribute to persistently
poor glycaemic control in individuals with type 2 diabetes.
A combination of factors ascribed to patients (e.g. fear of
hypoglycaemia/injections, complex treatment regimen,
polypharmacy), physicians (e.g. poor/ineffective commu-
nication, insufficient knowledge and support) or healthcare
systems (e.g. lack of time/resource for physicians, lack of
tools for patient/physician to monitor insulin titration, lack
of medical coverage), may be particularly relevant in
developing countries where development of infrastructure
and capacity cannot cope with the rapid rate of increase in
diabetes [36, 37]. Other patient-related factors, such as
older age, higher education level and short disease dura-
tion, have also been reported to be associated with
improved glycaemic control [38, 39]; it is possible that
lifestyle factors, acceptance of diagnosis and adherence
may all contribute in these cases.
The present study has some limitations. The cross-sectional
nature of the survey provides a ‘snapshot’ of practice at any
one time; therefore, these observations only allow us to form
hypotheses, and cannot infer causality. The self-selecting
nature of the patient population should be considered, as those
with the poorest control are most likely to visit the clinic;
therefore, glycaemic control in the general population may
be higher than that shown here. All data were completed by
the attending physicians with potential bias in interpretation
and recall. Due to the pragmatic nature of the survey, no adju-
dication was conducted for the reported complications. The
varying degrees of local support in implementing the survey
also mean that different countries/regions were included/
excluded in different waves. These variables add to the hetero-
geneity of practice, although we have adjusted for major
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variables (notably age, sex, disease duration and region) when
analysing secular trends. Despite these limitations, we believe
that aspects of this study such as its large, global population,
long duration (12 years) and the practice of structured data
collection using predefined variables have provided valuable
real-world evidence from areas hit hardest by the diabetes
epidemic, where data are lacking to inform practice and
policies.
In conclusion, in this 12 year study, poor and worsening
glycaemic control was observed in individuals with type 2
diabetes. These real-world data highlight an urgent need
for improvement in practice environments, workflow and
team structure; such amendments would allow early
assessment of patients and identification of unmet needs,
thus empowering individuals to improve self-management
and consequently glycaemic control. These changes will
need to be supplemented by institutional support through
capacity building, and policies that promote good diabetes
care; these would ideally encompass improved accessibil-
ity to and affordability of medications and monitoring
accessories, in both developing countries and subpopula-
tions of patients with poor literacy/low incomes in devel-
oped countries [5, 40]. Altogether, these could lead to a
successful improvement in diabetes care and clinical
outcomes in individuals with type 2 diabetes living in
developing countries.
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